Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by ...

On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...

A new class of weight-loss drugs known as GLP-1s are proving to be game changers for people with obesity. They’re also minting billions for pharmaceutical companies, especially the companies that ...

According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to ...

It's been an excellent year for Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech company. Viking Therapeutics' leading candidate, VK2735, is a potential GLP-1 weight loss medicine. It reported ...

Eli Lilly moves to defend FDA's tirzepatide shortage resolution amid criticism over supply issues and compounding pharmacy claims.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 489.81% and ...

U.S. Surgeon General Vivek Murthy said Friday that two alcoholic drinks a day increases the risk for seven types of cancer, calling for cancer warning labels on alcohol.

James (illness) will play Tuesday night against Cleveland, Ryan Ward of Lakers Nation reports. James was upgraded to probable shortly before tipoff and has now been given the green light to play ...